108392-02-5

Basic information

• Product Name: 1,2-DI[CIS-9-OCTADECENOYL]-SN-GLYCERO-3-PHOSPHATE SODIUM SALT
• Synonyms: PHOSPHATIDIC ACID, DIOLEOYL, SODIUM SALT;1,2-DIOLEYOYL-SN-GLYCERO-3-PHOSPHATE NA;1,2-DI[CIS-9-OCTADECENOYL]-SN-GLYCERO-3-PHOSPHATE SODIUM SALT;L-ALPHA-PHOSPHATIDIC ACID, DIOLEOYL SODIUM SALT;L-A-phosphatidic acid dioleoyl sodium;1,2-di(cis-9-octadecenoyl)-sn-glycerol 3-phosphate sodium salt;l-α-phosphatidic acid, dioleoyl sodium salt;1,2-Dioleoyl-sn-glycero-3-phosphoric acid monosodium salt
• CAS NO: 108392-02-5
• Molecular Formula: C₃₉H₇₂O₈P*Na
• Molecular Weight: 744.93
• Mol File: 108392-02-5.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: −20°C
• CAS DataBase Reference: 1,2-DI[CIS-9-OCTADECENOYL]-SN-GLYCERO-3-PHOSPHATE SODIUM SALT(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-DI[CIS-9-OCTADECENOYL]-SN-GLYCERO-3-PHOSPHATE SODIUM SALT(108392-02-5)
• EPA Substance Registry System: 1,2-DI[CIS-9-OCTADECENOYL]-SN-GLYCERO-3-PHOSPHATE SODIUM SALT(108392-02-5)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 108392-02-5(Hazardous Substances Data)

Usage

Uses

OOPA is used in the method for preparing liposome comprising ultrasound reactive microbubble for drug delivery and liposome using same.

InChI:InChI=1/C39H73O8P.Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(40)45-35-37(36-46-48(42,43)44)47-39(41)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h17-20,37H,3-16,21-36H2,1-2H3,(H2,42,43,44);/b19-17+,20-18+;

Upstream product

• 6085-36-5 oleic anhydride 

Downstream Products

• 4004-05-1 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
• 4235-95-4 dioleoylphosphatidylcholine 

Relevant articles and documents

The development of improved cationic lipids for gene transfer into cystic fibrosis airway epithelial cells

In an effort to improve the efficiency of cationic lipid mediated gene transfer, over 90 novel cationic lipids of diverse structural types were synthesized and evaluated in vitro. Four cationic lipids derived from phospholipids were examined. The most promising cationic lipid formulations were tested in vivo by intranasal or transtracheal instillation into the lungs of BALB/c mice. The most active formulations gave CAT reporter gene expression levels which are greater than 500 fold over that which could be attained using free DNA alone. Certain cationic lipid formulations have been shown to facilitate substantial expression of the CFTR (cystic fibrosis transmembrane conductance regulator) gene in vitro as determined by the SPQ and Ussing Chamber assays.